Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Genentech Inc. is trying a different approach to go after difficult drug targets, partnering May 9 with New York-based start-up Lodo Therapeutics Corp. on a collaboration to use the latter’s Metagenomics Technology Platform to identify novel molecules with therapeutic potential for multiple disease-related targets